Literature DB >> 28846491

Human papilloma virus vaccine for low and middle income countries: A step too soon?

Har Ashish Jindal1, Amanjot Kaur2, Sathiabalan Murugan1.   

Abstract

Cervical Cancer is the most common genital cancer in women in India. Human papilloma virus (HPV) causes precancerous lesions that often develop into cervical cancer suggesting that cervical cancer has an infective etiology and is potentially preventable by preventing HPV infection through the use of HPV vaccines. The incidence in developing nations is largely under-reported due to large population size, poor and incomplete database. HPV vaccine is being considered for inclusion in the immunization schedule of developing countries. An effective surveillance system for a vaccine requires that the baseline incidence, prevalence, and mortality rates of cervical cancer are established for a given population. The lessons learnt from the polio vaccine must be applied to every vaccine being introduced for its optimal utilization. HPV vaccines might be used as a cost-effective scientific intervention to prevent cervical cancer but need to be combined with good screening methods in developing countries for a paradigm shift in the management of cervical cancer.

Entities:  

Keywords:  Cervical; HPV; cancer; vaccine

Mesh:

Substances:

Year:  2017        PMID: 28846491      PMCID: PMC5703377          DOI: 10.1080/21645515.2017.1358837

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  15 in total

1.  Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal:  Lancet       Date:  2006-04-15       Impact factor: 79.321

Review 2.  Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness.

Authors:  I Mattheij; A M Pollock; P Brhlikova
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

Review 3.  Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.

Authors:  Edward P Armstrong
Journal:  J Manag Care Pharm       Date:  2010-04

4.  Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Authors:  Luisa L Villa; Kevin A Ault; Anna R Giuliano; Ronaldo L R Costa; Carlos A Petta; Rosires P Andrade; Darron R Brown; Alex Ferenczy; Diane M Harper; Laura A Koutsky; Robert J Kurman; Matti Lehtinen; Christian Malm; Sven-Eric Olsson; Brigitte M Ronnett; Finn Egil Skjeldestad; Margareta Steinwall; Mark H Stoler; Cosette M Wheeler; Frank J Taddeo; Jimmy Yu; Lisa Lupinacci; Radha Railkar; Rocio Marchese; Mark T Esser; Janine Bryan; Kathrin U Jansen; Heather L Sings; Gretchen M Tamms; Alfred J Saah; Eliav Barr
Journal:  Vaccine       Date:  2006-05-15       Impact factor: 3.641

5.  Trends in cancer incidence in Chennai city (1982-2006) and statewide predictions of future burden in Tamil Nadu (2007-16).

Authors:  R Swaminathan; V Shanta; J Ferlay; S Balasubramanian; F Bray; R Sankaranarayanan
Journal:  Natl Med J India       Date:  2011 Mar-Apr       Impact factor: 0.537

Review 6.  An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.

Authors:  Michelle Forcier; Najah Musacchio
Journal:  Dermatol Ther       Date:  2010 Sep-Oct       Impact factor: 2.851

7.  Human papillomavirus infection is transient in young women: a population-based cohort study.

Authors:  M Evander; K Edlund; A Gustafsson; M Jonsson; R Karlsson; E Rylander; G Wadell
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

8.  Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.

Authors:  Kevin A Ault
Journal:  Lancet       Date:  2007-06-02       Impact factor: 79.321

9.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Authors:  Diane M Harper; Eduardo L Franco; Cosette Wheeler; Daron G Ferris; David Jenkins; Anne Schuind; Toufik Zahaf; Bruce Innis; Paulo Naud; Newton S De Carvalho; Cecilia M Roteli-Martins; Julio Teixeira; Mark M Blatter; Abner P Korn; Wim Quint; Gary Dubin
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

10.  Trends in breast, ovarian and cervical cancer incidence in Mumbai, India over a 30-year period, 1976-2005: an age-period-cohort analysis.

Authors:  P K Dhillon; B B Yeole; R Dikshit; A P Kurkure; F Bray
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

View more
  2 in total

1.  Developing a framework to describe stigma related to cervical cancer and HPV in western Kenya.

Authors:  Ramya Ginjupalli; Rachel Mundaden; Yujung Choi; Emily Herfel; Sandra Yvonne Oketch; Melissa H Watt; Breandan Makhulo; Elizabeth Anne Bukusi; Megan Huchko
Journal:  BMC Womens Health       Date:  2022-02-11       Impact factor: 2.809

2.  Acceptance and Willingness to Pay for Vaccine Against Human Papilloma Virus (HPV) Among Parents of Boys in Central Vietnam.

Authors:  Lan Hoang Nguyen; Thuy Bich Thi Le; Nhu Quynh Nguyen Le; Nhan Thanh Thi Tran
Journal:  Front Public Health       Date:  2022-03-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.